The Drop of Blood That Was Never Going to Work

In 2003, a nineteen-year-old Stanford dropout named Elizabeth Holmes founded a company she called Theranos, with the stated mission of developing a blood-testing device that could perform hundreds of laboratory tests using a single drop of blood from a fingerstick. The technology, if it had worked, would have collapsed the cost and complexity of conventional clinical laboratory testing — an industry that, even today, processes billions of conventional blood draws annually. The technology did not work. The company nonetheless raised more than seven hundred million dollars from sophisticated investors, achieved a peak valuation of approximately nine billion dollars, and operated for thirteen years before its claims were exposed.

The exposure began with a series of investigative reports in 2015 by John Carreyrou of the Wall Street Journal. The technology, as deployed in commercial settings, had been performing many tests on standard third-party laboratory equipment that had been quietly modified and incorporated into the Theranos product workflow. The proprietary "Edison" device, when used at all, was producing results of dubious accuracy. Thousands of patient samples had been processed; some had reportedly produced medically consequential errors.

The Capital Structure. The Theranos investor base included Rupert Murdoch, Larry Ellison, the Walton family, the DeVos family, Henry Kissinger as a board member, James Mattis as a board member, George Shultz as a board member. The board carried unusual political and military weight; it carried unusual little laboratory-science weight. The capital was raised against a particular kind of charismatic founder pitch that the technical community had been skeptical of from early on. Forbes named Holmes the youngest self-made female billionaire in 2014. The technical skepticism was not, at the time, reflected in the capital markets.

The Reckoning. The 2015-2018 unwinding was, by any standard, brutal. The Securities and Exchange Commission charged Holmes with fraud. The company was dissolved. Holmes and the chief operating officer Sunny Balwani were eventually convicted of multiple counts of fraud in 2022. Holmes received an eleven-year prison sentence. The investor losses, by aggregate, exceeded a billion dollars.

The Theranos case is now taught in business schools as a particular kind of pattern recognition exercise: when a charismatic founder makes claims about technical capability that the underlying technical community cannot verify, the gap between the claims and the verification is where the fraud lives. The capital markets, briefly, were unable to distinguish the founder's pitch from the underlying technology. The corrective came late, but it came. The lesson is being printed in real time, and the next charismatic biotech founder is being received with rather more skepticism than the one before.